BMNDF News and Press, Biomind Labs From 11/04/22

BMNDF - Biomind Labs Announces Positive Initial Results From Its Phase II Trial on Its BMND01 Candidate for Treatment Resistant Depression

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and...

BMNDF - Biomind Labs Announces Pre-IND Meeting Request Granted by FDA for Its New Chemical Entity Triptax(TM) Targeting Treatment-Resistant Depression

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and...

BMNDF - Biomind stock rises 11% on license to start project for microneedle use in drug delivery

Biomind Labs ( OTCQB:BMNDF ) stock rose ~11% on Sept. 27 after the company said it received a controlled substances license to start production of a novel transdermal drug delivery system. Biomind Labs and Queen’s University of Belfast will begin an eight-month ...

BMNDF - Biomind Labs and Queen's University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and...

BMNDF - Biomind finishes dosing in trial of inhalation therapy for treatment-resistant depression

Biomind Labs ( OTCQB:BMNDF ) said it completed dosing of 30 healthy people in a phase 2 trial of its drug BMND01 for treatment-resistant depression. "The results of this first part of the world’s first clinical trial to test an inhaled formulation of DMT are expecte...

BMNDF - Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and...

BMNDF - Biomind Labs Appoints Former FDA Director Dr. Thomas Laughren as Medical Advisor for Clinical Trials

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and...

BMNDF - Biomind Labs Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Treatment of Depression and Anxiety in Alzheimer's Disease

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and...

Company Name:	Biomind Labs
Stock Symbol:	BMNDF
Market:	OTC
Website:	biomindlabs.com